After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...
Zacks.com on MSN1h
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for UrticariaSanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
GlobalData on MSN3d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticariaThe FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for ...
Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback